HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more
HUTCHMED (China) Limited (HMDCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.029x
Based on the latest financial reports, HUTCHMED (China) Limited (HMDCF) has a cash flow conversion efficiency ratio of -0.029x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.45 Million) by net assets ($1.24 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HUTCHMED (China) Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how HUTCHMED (China) Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HUTCHMED (China) Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED (China) Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quaker Chemical Corporation
NYSE:KWR
|
0.038x |
|
Hebei Yangyuan ZhiHui Beverage Co Ltd
SHG:603156
|
-0.058x |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
-0.041x |
|
Poco Holding Co Ltd
SHE:300811
|
0.018x |
|
Linktel Technologies Co. Ltd. A
SHE:301205
|
0.003x |
|
HEXPOL AB ser. B
LSE:0R7O
|
0.078x |
|
Calumet Specialty Products Partners
NASDAQ:CLMT
|
-0.223x |
|
Manappuram Finance Limited
NSE:MANAPPURAM
|
-0.196x |
Annual Cash Flow Conversion Efficiency for HUTCHMED (China) Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of HUTCHMED (China) Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.25 Billion | $-64.75 Million | -0.052x | -8137.94% |
| 2024-12-31 | $771.85 Million | $497.00K | 0.001x | -99.78% |
| 2023-12-31 | $743.39 Million | $219.26 Million | 0.295x | +169.93% |
| 2022-12-31 | $636.87 Million | $-268.60 Million | -0.422x | -114.67% |
| 2021-12-31 | $1.04 Billion | $-204.22 Million | -0.196x | -64.27% |
| 2020-12-31 | $518.95 Million | $-62.07 Million | -0.120x | +53.75% |
| 2019-12-31 | $312.90 Million | $-80.91 Million | -0.259x | -224.54% |
| 2018-12-31 | $412.25 Million | $-32.85 Million | -0.080x | -332.07% |
| 2017-12-31 | $484.97 Million | $-8.94 Million | -0.018x | +60.68% |
| 2016-12-31 | $204.06 Million | $-9.57 Million | -0.047x | +48.90% |
| 2015-12-31 | $102.28 Million | $-9.38 Million | -0.092x | -182.34% |
| 2014-12-31 | $119.88 Million | $13.36 Million | 0.111x | +132.36% |
| 2013-12-31 | $104.84 Million | $5.03 Million | 0.048x | -74.38% |
| 2012-12-31 | $83.65 Million | $15.66 Million | 0.187x | +178.34% |
| 2011-12-31 | $77.33 Million | $5.20 Million | 0.067x | +123.36% |
| 2010-12-31 | $68.81 Million | $-19.82 Million | -0.288x | -286.53% |
| 2009-12-31 | $75.30 Million | $11.63 Million | 0.154x | +191.37% |
| 2008-12-31 | $84.43 Million | $-14.27 Million | -0.169x | -91.86% |
| 2007-12-31 | $97.61 Million | $-8.60 Million | -0.088x | -166.27% |
| 2006-12-31 | $109.98 Million | $-3.64 Million | -0.033x | -106.81% |
| 2005-12-31 | $-28.01 Million | $-13.60 Million | 0.485x | -- |